The licensing deal is substantial in value and focuses on the development of treatments for neurological disorders, an area that is often met with high demand and can lead to significant revenue streams if successful. The deal could positively impact Jazz Pharmaceuticals' stock in the short term as it may be viewed as a strategic move to strengthen its product pipeline and future growth prospects.